| Withdrawn | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC NCT06592664 | Lisata Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally A NCT06026943 | Alpha Tau Medical LTD. | N/A |
| Recruiting | A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Dr NCT07198659 | The First Affiliated Hospital of Air Force Medicial University | EARLY_Phase 1 |
| Recruiting | Efficacy of PERT for PEI in Unresectable Pancreatic Cancer. NCT06099119 | Hospital Clinico Universitario de Santiago | Phase 4 |
| Recruiting | Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobilia NCT06135896 | National Cancer Center, Korea | Phase 2 |
| Recruiting | Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) NCT06278454 | Chengdu New Radiomedicine Technology Co. LTD. | Phase 1 |
| Recruiting | A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advance NCT05657743 | Alpha Tau Medical LTD. | N/A |
| Active Not Recruiting | A Study of Suizenji in Patients With Unresectable Pancreatic Cancer NCT05601323 | SONIRE Therapeutics Inc. | N/A |
| Withdrawn | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer NCT05251038 | Devalingam Mahalingam | Phase 1 / Phase 2 |
| Recruiting | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer NCT04789486 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | FAZA PET/MRI Pancreas NCT04395469 | University Health Network, Toronto | N/A |
| Terminated | Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer NCT04698915 | Galera Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer NCT04002479 | Alpha Tau Medical LTD. | N/A |
| Unknown | Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreati NCT04093141 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | N/A |
| Completed | EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options NCT03602885 | Dana-Farber Cancer Institute | N/A |
| Completed | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable NCT03250273 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Bioinformation Therapy for Pancreatic Cancer NCT03239184 | Fuda Cancer Hospital, Guangzhou | Phase 2 / Phase 3 |
| Withdrawn | Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer NCT03117556 | University of Louisville | N/A |
| Active Not Recruiting | Pre-operative Treatment for Patients With Untreated Pancreatic Cancer NCT03138720 | HonorHealth Research Institute | Phase 2 |
| Completed | Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Ste NCT03891472 | Medical University of Silesia | Phase 2 |
| Unknown | EUS BD vs ERCP TP for Pancreatic Cancer NCT03063554 | Weill Medical College of Cornell University | N/A |
| Unknown | Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic C NCT02945267 | Chinese PLA General Hospital | Phase 4 |
| Active Not Recruiting | MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer NCT01972919 | Medical College of Wisconsin | Phase 2 |
| Active Not Recruiting | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or NCT02495896 | University of Southern California | Phase 1 |
| Completed | Improving Informed Consent for Palliative Chemotherapy NCT02282722 | Dana-Farber Cancer Institute | N/A |
| Completed | BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer NCT03627390 | Meabco A/S | Phase 2 |
| Terminated | RFA RCT for Pancreatic or Bile Duct Cancer NCT02166190 | Weill Medical College of Cornell University | N/A |
| Unknown | Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) NCT02041936 | University of Maryland, Baltimore | N/A |
| Unknown | Regional Versus Systemic Chemotherapy in the Treatment of Unresectable Pancreatic Cancer NCT01665625 | Air Force Military Medical University, China | N/A |
| Completed | Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonme NCT02035072 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Completed | Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Adv NCT01304160 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 / Phase 2 |